Actively Recruiting
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-07-01
39
Participants Needed
1
Research Sites
229 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as first-line treatment, the (repeated) use of LAT to ≤ 3 OP lesions and continuation of first-line osimertinib, improves the median progression-free survival by more than 3 months (i.e. PFS2-PFS1 = \>3 months).
CONDITIONS
Official Title
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male or female, 18 years of age or older
- Histological diagnosis of advanced NSCLC with an EGFR actionable mutation
- Receiving first-line targeted TKI therapy with osimertinib
- Radiologically confirmed response (at least stable disease) to osimertinib assessed 3 months after starting treatment
- Confirmed oligoprogression with 3 or fewer intra- or extracranial progressive disease sites eligible for LAT
- All progressive sites visible and suitable for LAT, not previously treated with radiation or radiofrequency
- Adequate baseline organ function to allow LAT
- Predicted life expectancy of 6 months or more
- Karnofsky Performance Status of 60% or higher and ECOG performance status 0-2
- Written informed consent provided
- If SBRT to abdominal area is planned, female participants must be surgically sterile, postmenopausal, or agree to use effective contraception during therapy
You will not qualify if you...
- More than 3 sites of progressive disease
- Progressive metastases not suitable for LAT
- Prior radiotherapy or radiofrequency ablation near the progressive lesion before study inclusion
- Co-morbidities that prevent safe use of LAT
- Psychological, sociological, or geographical issues that could impair study compliance
- Pregnancy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UZLeuven
Leuven, Belgium, 3000
Actively Recruiting
Research Team
P
Patrick Berkovic, MD
CONTACT
E
Els Wauters, MD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here